Charity Registration Number 1189246 

British Psoriatic Arthritis Consortium 

Report and Accounts 

31 March 2025 




## **British Psoriatic Arthritis Consortium** 

## **Report and accounts for the year ended 31 March 2025** 

## **Contents** 

||**Page**||
|---|---|---|
|**Charity information**||1|
|**Members' Annual Report**||1|
|**Statement of Members' responsibilities**||4|
|**Independent Accountant's Report**||7|
|**Statement of Financial Activities**||8|
|**Balance sheet**||10|
|**Notes to the accounts**||11|





## **British Psoriatic Arthritis Consortium** 

## **Members' Annual Report for the year ended 31 March 2025** 

The Members present their Report and Accounts for the year ended 31 March 2025. 

## **Reference and administrative details** 

## _**The charity name**_ 

The legal name of the charity is:- British Psoriatic Arthritis Consortium. 

The charity is also known by its operating name, Brit-PACT. 

## _**The charity's areas operation and UK charitable registration**_ 

The charity is registered in England & Wales with the Charity Commission in England & Wales (CCEW)  with charity number 1189246. 

The charity does not operate in any overseas jurisdictions. 

## _**Legal structure of the charity**_ 

The charity is constituted as a Charitable Incorporated Organisation (CIO) in England & Wales. The governing document of the charity is the constitution of the CIO as approved by the Charity Commission in England & Wales (CCEW) . 

The governing document is dated 

20 April 2020 

There are no restrictions in the governing documents on the operation of the Charity or on its investment powers other than those imposed by Charity Law. 

The trustees are all  individuals. 

## _**The principal operating address and website of the charity are:-**_ 

Department D1, Wolfson Building 

Royal United Hospital, Combe Park Bath,  BA1 3NG 

www.britpact.org.uk 

_**The Members in office on the date the report was approved were:-**_ 

L Coates N Gullick P Helliwell J Packham W Tillet (reappointed 11/10/2024) T Gudu C Allen P Ho A Kelly S Mukherjee L Hailey (resigned 11/10/2024) R Hum H Johsson (resigned 11/10/2024) J Bluett M Jasim (appointed 11/10/2024) A Elliot (appointed 11/10/2024) 

The following persons served as Members during the year ended 31 March 2025 :- 

The members who served as a member in the reporting period were as shown above, and there were no changes during the year, or in the period between the year end and the approval of the accounts. 

1 



## **British Psoriatic Arthritis Consortium** 

## **Members' Annual Report for the year ended 31 March 2025** 

## **Objects and activities of the charity** 

## _**The purposes of the charity as set out in its governing document**_ 

The object of the CIO is to relieve sickness and to preserve and protect good health for the public benefit by promoting medical knowledge, and excellence through education and research with particular reference to the diseases of psoriasis and psoriatic arthritis. 

## _**The main activities undertaken in relation to those purposes during the year**_ 

In this financial year, Brit-PACT continues to support education and research into psoriatic arthritis (PsA) in the UK. 

The main conference event was the annual meeting in hybrid format in November 2024 in Birmingham. This meeting was organised and hosted by Professors Coates and Helliwell and Dr Tania Gudu.  The meeting had 86 attendees (47 in person and 39 online).  Meeting highlights included a presentation on obesity by Dr Jonathan Hazlehurst and lectures plus group discussion on axial disease in PsA led by Professor Jon Packham and Mr Dale Webb. The meeting also included a patient-led session, and a session led by Julie Begum, a nurse specialist. There were also abstract prize-winning presentations by rheumatology fellows and Brit-PACT project updates. The meeting received very positive feedback from attendees with 60% rating the meeting highly relevant to their educational needs, and a further 40% agreeing that the meeting was mostly relevant with regard to this objective. 

The pilot research grant scheme continues with the award this year of just one research grant to an academic group in Manchester. All grants submitted were asked to include at least one of the ‘Top 10’ items identified in the James Lind Priority Setting Partnership, which had been funded previously by Brit-PACT. Progress with previous pilot grant projects was reported at the Annual Meeting in Birmingham in November 2024 (see below). We have continued to support other research with external funding. This includes the SEQUENCE study, which was launched in 2022, and collected data on use of high cost treatments for Psoriatic Arthritis in Rheumatology Departments across the UK, with high engagement from the general Brit-PACT membership. This study has now been completed – updates on this project were given by Dr William Tillett at the annual meeting and a publication is in preparation. 

Brit-PACT continues to provide support and updates to the British Society for Rheumatology on its activities and provides support to subcommittees of the BSR such as recommendations for biologic use in psoriatic arthritis. 

## _**The main activities undertaken during the year to further the charity's purpose for the public benefit.**_ 

As in previous years the main activities of Brit-PACT during the last year were educational meetings and the award of pilot research grants and Brit-PACT-led research projects, both of which fulfilled the purpose of the charity and will be of benefit the charity’s beneficiaries. Members of the Executive Committee took part in an external project in 2023 to create consensus recommendations for diagnosis, assessment and management of psoriatic arthritis, including its comorbidities. These were published in 2024 in Rheumatology, the flagship journal of the British Society for Rheumatology.  Results from a previous survey performed by Brit-PACT on combination advanced therapies were also published in Rheumatology in early 2025. 

The trustees have had regard to the Charity Commission's guidance on public benefit in managing the activities of the charity. 

2 



## **British Psoriatic Arthritis Consortium** 

## **Members' Annual Report for the year ended 31 March 2025** 

## _**The main achievements and performance of the charity during the year**_ 

1.Psoriatic Arthritis Education for Health Care Professionals Brit-PACT continues to conduct educational meetings for rheumatology health care professionals and to disseminate meeting highlights to membership. 

2.Funding and supporting Psoriatic Arthritis Research Brit-PACT has funded one further pilot research project. This was awarded to Dr Steven Zhao Sizheng from the University of Manchester with a project entitled: ‘Blood Biomarker for Timely Diagnosis of Psoriatic Arthritis’. 

3.Sharing patient perspective on living with psoriatic disease. The patient partners continue to share the patient perspective with Clinicians & HCPs and collaborate with other organisations to inform research direction. One of the patient members of the Steering Committee presented at the annual meeting. The patient group has also advised on Psoriatic Arthritis consensus recommendations and engaged with other activities including surveys, workshops and assisting with grant applications as well as to a number of other engagement/involvement opportunities. The patient group has also contributed to the iPROLEPSIS advisory group: The EU-unded iPROLEPSIS project aims to improve early detection of PsA symptoms and reduce diagnostic delay. Finally, the patient partner group has also contributed to Trailblazers, where there are opportunities for patients to engage such as completing a survey, helping with grant applications, and participation in workshops. 

## _**The difference the charity's performance during the year has made to the beneficiaries of the charity**_ 

Recognised by NIHR and HTA the James Lind PSP has prioritised research themes for both researchers and funders and will focus direction of research for the future, including those projects supported or funded by BritPACT.  Brit-PACT educational updates and virtual meetings provide educational opportunities for rheumatologists in training and rheumatology teams in the UK. The Brit-PACT patient partners also benefit from these educational activities as well as providing support to others both in person and electronically. 

## _**The degree to which the achievements and performance during the year have benefited wider society.**_ 

The results of the PsA James Lind Priority Setting Partnership “Top 10” is still being used to feed into grant proposals so that research prioritises area important to clinicians, patients and carers. The JLPSP will continue to help both researchers and funders to prioritise research in this area and help prevent the impact of psoriatic arthritis on patients, carers, and employers, as well as to raise the profile of psoriatic arthritis from a societal point of view. The patient partners provide an alternative perspective to psoriatic arthritis and help professionals and patients alike to achieve better, more holistic, care. 

## **Structure, governance and management of the charity** 

## _**The methods used to recruit and appoint new charity trustees.**_ 

The Brit-PACT constitution incorporates elections for major Executive committee positions. The Executive Committee (trustees) includes rheumatologists in training, allied health professionals and patient partners. In line with the constitution of the Charity nominations are sought annually for new Executive committee members as vacancies become available, and voting is by a single vote of all members, the majority vote taken as the definitive result. In this calendar year there have been two retirements from the Executive (Dr Hanna Johnsson, Mrs Louise Hailey), three members re-elected for a second term (Profs Philip Helliwell and Jon Packham & Dr Sandeep Mukherjee)  and two new medical members elected (Dr Muhamad Jasim & Dr Ashley Elliott), and one AHP member (Ms Julie Begum). 

3 



## **British Psoriatic Arthritis Consortium** 

## **Members' Annual Report for the year ended 31 March 2025** 

Bankers Solicitors Accountants 

Unity Trust Bank, 4 Brindley Place, Birmingham B1 2JB Stone King LLP, 13 Queen Square, Bath BA1 2HJ DR Hicks, 107 Penn Hill Road, Bath BA1 3RU 

## **Financial review** 

## _**The charity's financial position at the end of the year ended 31 March 2025**_ 

The financial position of the charity at 31 March 2025 and comparatives for the prior period, as more fully detailed in the accounts, can be summarised as follows:- 

|Restricted Revenue Funds<br>**Total Funds**<br>Unrestricted Revenue Funds available for the<br>general purposes of the charity<br>**Net income**|**2025**<br>**£**<br>(40,427)<br>79,272<br>52,648<br>131,920|**2024**<br>**£**<br>(87,339)|
|---|---|---|
|||112,649<br>59,698|
|||172,347|



## _**Financial review of the position at the reporting date 31 March 2025**_ 

The members consider the financial performance by the charity during the year to have been satisfactory. 

## _**Policies on reserves**_ 

The board of trustees agree to run the charity with reserves sufficient to meet expenses for approximately one year. 

## _**Availability and adequacy of assets of each of the funds**_ 

The board of trustees is satisfied that the charity's assets in each fund are available and adequate to fulfil its obligations in respect of each fund. 

## **Details of The Independent Examiner** 

## Dione Hicks 

Member of the Institute of Chartered Accountants in England & Wales 

107 Penn Hill Road 

Bath BA1 3RU 

4 



## **British Psoriatic Arthritis Consortium** 

## **Members' Annual Report for the year ended 31 March 2025** 

## **Statement of Members' Responsibilities** 

The charity's trustees are responsible for the preparation of the accounts in accordance with the terms of  the Charities Act 2011 and the Charities (Accounts and Reports) Regulations 2008. Notwithstanding the explicit requirement in the extant statutory regulations,the Charities (Accounts and Reports) Regulations 2008, to prepare the financial statements in accordance with the SORP 2005, in view of the fact that the SORP 2005 has been withdrawn, the Members determined to interpret this responsibility as requiring them to follow current best practice and prepare the accounts according to the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities)  2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), . 

In particular, charity law requires the Members, if they prepare accounts on an accruals basis, to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity as at the end of the financial year and of the surplus or deficit of the charity. In preparing those financial statements the Members are required to :- 

- to prepare the accounts in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). 

- select suitable accounting policies and apply them consistently; 

- make judgements and estimates that are reasonable and prudent; 

- prepare the financial statements on the going concern basis unless it is inappropriate 

to presume that the charity will continue in business; 

- state whether applicable accounting standards and statements of 

recommended practice have been followed, subject to any material 

departures disclosed and explained in the financial statements; 

The law requires that the trustees must not approve the accounts unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for the year. 

The Members are also responsible for maintaining adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which are sufficient to show and explain the charity's transactions and enable them to ensure that the financial statements comply with regulations made under the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

The Members are also responsible for the contents of the Members' report, and the statutory responsibility of the Independent Examiner in relation to the Members' report is limited to examining the report and ensuring that , on the face of the report, there are no material inconsistencies with the figures disclosed in the financial statements. 

This report was approved by the board of trustees on 26 November 2024. 


P Helliwell Trustee 

5 



## **British Psoriatic Arthritis Consortium** 

## **Report of the Independent Examiner to the Members of the charity on the accounts for the year ended 31 March 2025** 

I report to the Members on my examination of the financial statements of the charity on pages 9 to 18 for the year ended 31 March 2025 which have been prepared in accordance with the Charities Act 2011 (the Act) and  with the Financial Reporting Standard 102, (effective 1st January 2016) as modified by FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities)  2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , and under the historical cost convention and the accounting policies set out on page 11. 

## **Respective responsibilities of the Members and the Independent Examiner and the basis of the report** 

As described on page 4, you, the charity's Members, are responsible for the preparation of the financial statements in accordance with the Charities Act 2011 and all other applicable law and with United Kingdom Generally Accepted Accounting Practice, applicable to smaller entities, and for being satisfied that the financial statements give a true and fair view. 

The Members consider that the audit requirement of  Section 144(1) of the Charities Act 2011 (the Act) does not apply, and that there is no requirement in the Governing Document for the conducting of an audit. As a consequence, the Members have elected that the financial statements be subject to independent examination. 

Having satisfied myself that the financial statements are not required to be audited under any legal provision, or otherwise, and are eligible for independent examination, it is my responsibility to:- 

a) examine the financial statements of the charity under Section 145 of the Act; 

b) follow the applicable procedures in the Directions given by the Charity Commission under section 145(5)(b) of the Act. 

## **Basis of Independent Examiner's Statement and scope of work undertaken** 

I report in respect of my examination of the charity's financial statements carried out under s145 of the Act. In carrying out my examination, I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act setting out the duties of an independent examiner in relation to the conducting of an independent examination.  An independent examination includes a review of the accounting records kept by the charity  and of the accounting systems employed by the charity and a comparison of the financial statements presented with those records. It also includes consideration of any unusual items or disclosures in the financial statements, and seeking explanations from you, as Members, concerning such matters. The purpose of the examination is to establish as far as possible that there have been no breaches of charity legislation and that, on a test basis of evidence relevant to the amounts and disclosures made, the financial statements comply with the SORP. 

The procedures undertaken do not provide all the evidence that would be required in an audit, and information supplied by the Members in the course of the examination is not subjected to audit tests or enquiries and does not cover all the matters that an auditor would consider in arriving at an opinion. The planning and conduct of an audit goes beyond the limited assurance that an independent examination can provide 

Consequently, I do not express an audit opinion on the view given by the financial statements, and in particular, I express no opinion as to whether the financial statements give a true and fair view of the affairs of the charity, and my report is limited to the matters set out in the statement below. 

I planned and performed my examination so as to satisfy myself that the objectives of the independent examination are achieved and before finalising the report I obtained written assurances from the Members of all material matters. 

## **Independent Examiner's Statement, Report and Opinion** 

Subject to the limitations upon the scope of my work as detailed above, I have completed my examination: and can confirm that:- 

6 



## **British Psoriatic Arthritis Consortium** 

This  is a report in respect of an examination carried out under 145 of the Act  and in accordance with Directions given by the Charity Commission under section 145(5)(b) of the Act which may be applicable; 

and that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:- 

accounting records were not kept in respect of the charity as required by  with Section 130 of The Charities Act 2011; 

the financial statements do not accord with those records; or 

the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view, which is not a matter considered as part of an independent examination; 

have not been prepared in accordance with  the methods and principles set out in the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities)  2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP). 

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached. 

## **Signed:-** 


Dione Hicks - Independent Examiner 

Chartered Accountants 107 Penn Hill Road Bath BA1 3RU 

This report was signed on 26 November 2024 

7 



## **British Psoriatic Arthritis Consortium** 

## **Statement of Financial Activities for the year ended 31 March 2025** 

|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>**Income & Endowments from:**<br>Donations & Legacies<br>A1<br>25,142<br>Investments<br>A4<br>246<br>**Total income**<br>**A**<br>**25,388**<br>**Expenditure on:**<br>Charitable activities<br>B2<br>58,765<br>**Total expenditure**<br>**B**<br>**58,765**<br>**Net income for the year**<br>**(33,377)**<br>**Net income after transfers**<br>**A-B-C**<br>**(33,377)**<br>**(33,377)**<br>**Reconciliation of funds:-**<br>**E**<br>**Total funds brought forward**<br>112,649<br>**Total funds carried forward**<br>**79,272**<br>**SORP**<br>**Ref**<br>**Net movement in funds**|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-<br>-<br>**-**<br>7,050<br>**7,050**<br>**(7,050)**<br>**(7,050)**<br>**(7,050)**<br>59,698<br>**52,648**|**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**25,142**<br>**246**<br>**25,388**<br>**65,815**<br>**65,815**<br>**(40,427)**<br>**(40,427)**<br>**(40,427)**<br>**172,347**<br>**131,920**|**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>43,353<br>212|
|---|---|---|---|
||||**43,565**|
||||130,904|
||||**130,904**|
|||||
||||**(87,339)**|
||||**(87,339)**|
||||**(87,339)**<br>259,686|
||||**172,347**|



The 'SORP Ref' indicated above is the classification of income set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the Balance Sheet. 

A separate Statement of Total Recognised Gains and Losses  is not required as this statement includes all recognised gains and losses. 

All the prior year transactions were unrestricted items, and no further analysis is required 

All activities derive from continuing operations 

**The notes attached on pages 11 to 18 form an integral part of these accounts.** 

8 



## **British Psoriatic Arthritis Consortium** 

## **Balance Sheet as at 31 March 2024** 

|||**SORP**|||||
|---|---|---|---|---|---|---|
||Note|**Ref**||**2025**||**2024**|
|||||**£**||**£**|
|**Current assets**||B|||||
|Debtors|6|B2|5,713||-||
|Cash at bank and in hand||B4|128,688||194,994||
|**Total current assets**|||134,401||194,994||
|**Creditors: amounts falling due within one**|||||||
|**year**|7|C1|(2,481)||(22,647)||
|**Net current assets**||||131,920||172,347|
|**The total net assets of the charity**||||**131,920**||**172,347**|
|**The total net assets of the charity are funded by the funds**|||**of the charity, as follows:-**||||



|**Restricted funds**<br>Restricted Revenue Funds<br>11<br>D2<br>52,648<br>**Unrestricted Funds**<br>Unrestricted Revenue Funds<br>11<br>D3<br>79,272<br>**Designated Funds**<br>**Total charity funds**|59,698<br>52,648<br>112,649<br>79,272<br>**131,920**|59,698<br>112,649|
|---|---|---|
|||**172,347**|



The 'SORP Ref' indicated above is the classification of Balance Sheet items as set out in the formal SORP documents. As required by paragraph 4.60 of the SORP, the brought forward and carried forward funds above have been agreed to the SOFA.. 

The Members acknowledge their responsibilities for complying with the requirements of charity legislation with respe 

The charity is subject to Independent Examination under charity legislation, and the report of the Independent Examiner is on page 8. 

The Members are satisfied that, although the charity is not registered under the Companies Acts, if it were so registered, it would be eligible to prepare accounts in accordance with the provisions in Part 15 of the Companies Act 2006. applicable to companies subject to the small companies regime. 


## **P Helliwell** 

Trustee 

Approved by the board of trustees on 26 November 2024 

**The notes attached on pages 11 to 18 form an integral part of these accounts.** 

9 



## **British Psoriatic Arthritis Consortium** 

## **Notes to the Accounts for the year ended 31 March 2025** 

## **1 Accounting policies** 

## _**Policies relating to the production of the accounts.**_ 

## **Basis of preparation and accounting convention** 

The accounts have been prepared on the accruals basis, under the historical cost convention, and in accordance with the Financial Reporting Standard 102, (effective 1st January 2016) and 'FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities)  2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP), published by the Charity Commission in England & Wales (CCEW) , effective January 2016, , and in accordance with all applicable law in the charity's jurisdiction of registration, except that the charity has prepared the financial statements in accordance with the FRS 102 SORP (Statement of Recommended Practice for Accounting and Reporting by Charities)  2015, (as amended by the Bulletin issued in October 2018 and applicable to all accounting periods beginning on or after 1st January 2019), (The SORP),  in preference to the previous SORP, the SORP 2005, which has been withdrawn, notwithstanding the fact that the extant statutory regulations, the Charities (Accounts and Reports) Regulations 2008 refer explicitly to the SORP 2005. This has been done to accord with current best practice. 

## **Going Concern** 

Under 3.38 and to comply with 3.14, if there are no uncertainties about going concern this MUST be stated. Under 3.39, if there are uncertainties details must be given. Enter text here to comply 

Suggested normal text (whioch may require modification to meet the circumstances):- 

The charitable activities are entirely dependent on continuing grant aid and voluntary donations as well as trading revenues. As a consequence, the going concern basis is dependent on the future flow of these uncertain funding streams. Accordingly, the Trustees have obtained forecasts and, after reviewing the financial forecasts for future periods to 31 March 2021, the Trustees are satisfied that, at the time of approving the financial statements, it is appropriate  to adopt the going concern  basis  in preparing  the financial statements. Other than these matters, the Trustees are not aware of any material uncertainites about the charity's ability to continue as a going concern. 

## **Risks and future assumptions** 

The charity is a public benefit entity. 

## _**Policies relating to categories of income and income recognition.**_ 

## **Nature of income** 

Gross income represents the value, net of value added tax and discounts, of goods provided to customers and work carried out in respect of services provided to customers. 

## **Categories of Income** 

Income is categorised as income from exchange transactions (contract income) and income from non-exchange transactions (gifts), investment income and other income. 

**Income from exchange transactions** is received by the charity for goods or services supplied under contract or where entitlement is subject to fulfilling performance related conditions. The income the charity receives is approximately equal in value to the goods or services supplied by the charity to the purchaser. 

**Income from a non-exchange transaction** is where the charity receives value from the donor without providing equal value in exchange, and includes donations of money, goods and services freely given without giving equal value in exchange. 


10 



## **British Psoriatic Arthritis Consortium** 

## **Notes to the Accounts for the year ended 31 March 2025** 

## **Income recognition** 

Income, whether from exchange or non exchange transactions, is recognised in the statement of financial activities (SOFA) on a receivable basis, when a transaction or other event results in an increase in the charity’s assets or a reduction in its liabilities and only when the charity has legal entitlement, the income is probable and can be measured reliably. 

Dividends are accrued when the shareholder’s right to receive payment is established. 

Income subject to terms and conditions which must be met before the charity is entitled to the resources is not recognised until the conditions have been met. 

All income is accounted for gross, before deducting any related fees or costs. 

## _**Policies relating to expenditure on goods and services provided to the charity.**_ 

## **Recognition of liabilities and expenditure** 

A liability, and the related expenditure, is recognised when a legal or constructive obligation exists as a result of a past event, and when it is more likely than not that a transfer of economic benefits will be required in settlement, and when the amount of the obligation can be measured or reliably estimated.. 

Liabilities arising from future funding commitments and constructive obligations, including performance related grants, where the timing or the amount of the future expenditure required to settle the  obligation are uncertain, give rise to a provision in the accounts, which is reviewed at the accounting year end. The provision is increased to reflect any increases in liabilities, and is decreased by the utilisation of any provision within the period, and reversed if any provision is no longer required. These movements are charged or credited to the respective funds and activities to which the provision relates. 

## _**Policies relating to assets, liabilities and provisions and other matters.**_ 

## **Debtors** 

Debtors are measured at their recoverable amounts at the balance sheet date. 

## **Creditors and provisions** 

Creditors and provisions are measured at their recoverable amounts at the balance sheet date. 

## **Cash and bank balances** 

Cash held by the charity is included at the amount actually held and counted at the year end. Bank balances, whether in credit or overdrawn,  are shown at the amounts properly reconciled to the bank statements. 

## **Fund Accounting** 

Unrestricted funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity. 

There are no designated funds. 

Restricted funds are subjected to restrictions on their expenditure imposed by the donor or through the terms of an appeal or as implied by law. 

There are no endowment funds. 

11 



## **British Psoriatic Arthritis Consortium** 

## **Notes to the Accounts for the year ended 31 March 2025** 

## **2 Liability to taxation** 

The Trustees consider that the charity satisfies the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by chapter 3 part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively  on the specific  charitable  objects  of the charity and for no other purpose. Value Added Tax is not recoverable by the charity, and is therefore included in the relevant costs in the Statement of Financial Activities. 

## **3 Winding up or dissolution of the charity** 

If upon winding up or dissolution of the charity there remain any assets, after the satisfaction of all debts and liabilities, the assets represented by the accumulated fund shall be transferred to some other charitable body or bodies having similar objects to the charity. 

## **4 Significance of financial instruments to the charity's position** 

There are no significant implications of financial instruments to the Charity's positon. 

## **5 Remuneration and payments to Trustees and persons connected with them** 

No trustees or persons connected with them received any remuneration from the charity, or any related entity. 

## **6 Debtors** 

|Prepayments and accrued income<br>**7**<br>**Creditors: amounts falling due within one year**<br>Trade creditors<br>**8**<br>**Income and Expenditure account summary**<br>**At 1 April 2024**<br>Surplus for the year<br>**At 31 March 2025**|**2025**<br>**2024**<br>**£**<br>**£**<br>5,713<br>-<br>**2025**<br>**2024**<br>**£**<br>**£**<br>2,481<br>22,647<br>**2025**<br>**2024**<br>**£**<br>**£**<br>172,347<br>259,686<br>(40,427)<br>(87,339)|
|---|---|
||**131,920**<br>**172,347**|



- **9 No related party transactions** 

There were no transactions with related parties in the year. 

12 



## **British Psoriatic Arthritis Consortium** 

## **Notes to the Accounts for the year ended 31 March 2025** 

**10 Particulars of how particular funds are represented by assets and liabilities** 

|**At 31 March 2025**<br>Current Assets<br>Current Liabilities<br>**At 1 April 2024**<br>Current Assets<br>Current Liabilities|**Unrestricted**<br>**funds**<br>**£**<br>81,753<br>(2,481)|**Designated**<br>**funds**<br>**£**<br>-|**Restricted**<br>**Total**<br>**Total**<br>**funds**<br>**Funds**<br>**Funds**<br>**£**<br>**£**<br>**£**<br>52,648<br>**134,401**<br>**134,401**<br>-<br>**(2,481)**<br>**(2,481)**|
|---|---|---|---|
||**79,272**|**-**|**52,648**<br>**131,920**<br>**131,920**|
||**Unrestricted**<br>**funds**<br>**£**<br>135,296<br>(22,647)|**Designated**<br>**funds**<br>**£**<br>-<br>-|**Restricted**<br>**Total**<br>**Total**<br>**funds**<br>**Funds**<br>**Funds**<br>**£**<br>**£**<br>**£**<br>59,698<br>**194,994**<br>**194,994**<br>-<br>**(22,647)**<br>**(22,647)**|
||**112,649**|**-**|**59,698**<br>**172,347**<br>**172,347**|



**11 Change in total funds over the year as shown in Note 10 , analysed by individual funds** 

|**_Unrestricted and designated funds:-_**<br>Unrestricted Revenue Funds<br>**Total unrestricted and designated funds**<br>**_Restricted funds:-_**<br>Sequence Project<br>**Total restricted funds**<br>**Total charity funds**|**Funds**<br>**brought**<br>**forward from**<br>**2024**<br>**£**<br>112,649|**Movement**<br>**in funds in**<br>**2025**<br>**See Note 12**<br>**£**<br>(33,377)|**Funds carried**<br>**forward to**<br>**2026**<br>**£**<br>**£**<br>**£**<br>**-**<br>**79,272**<br>**79,272**<br>**Funds carried**<br>**forward to**<br>**2026**<br>**Transfers**<br>**between**<br>**funds in 2025**|
|---|---|---|---|
||**112,649**|**(33,377)**|**-**<br>**79,272**<br>**79,272**|
||59,698|(7,050)|-<br>**52,648**<br>**52,648**|
||**59,698**|**(7,050)**|**-**<br>**52,648**<br>**52,648**|
|||||
||**172,347**|**(40,427)**|**-**<br>**131,920**<br>**131,920**|



13 



## **British Psoriatic Arthritis Consortium** 

## **Notes to the Accounts for the year ended 31 March 2025** 

**12 Analysis of movements in funds over the year as shown in Note 11** 

|**_Unrestricted and designated funds:-_**<br>Unrestricted Revenue Funds<br>**_Restricted funds:-_**<br>Sequence Project|**Income**<br>**2025**<br>**£**<br>25,388<br>-|**Expenditure**<br>**2025**<br>**£**<br>(58,765)<br>(7,050)|**Other**<br>**Gains &**<br>**Movement**<br>**Movement**<br>**Losses**<br>**in  funds**<br>**in  funds**<br>**2025**<br>**2025**<br>**2025**<br>**£**<br>**£**<br>**£**<br>-<br>**(33,377)**<br>**(33,377)**<br>-<br>**(7,050)**<br>**(7,050)**|
|---|---|---|---|
||**25,388**|**(65,815)**|**-**<br>**(40,427)**<br>**(40,427)**|



## **The purposes for which the funds as detailed in note 11 are held by the charity 13 are:-** _**Unrestricted and designated funds:-**_ 

Unrestricted Revenue Funds 

These funds are held for the meeting the objectives of the charity, and to provide reserves for future activities, and , subject to charity legislation, are free from all restrictions on their use. 

Designated Revenue Funds _**Restricted funds:-**_ Restricted Revenue Funds 

There are no such funds held by the Charity. 

Funds specific for this pupose. 

## **14 Ultimate controlling party** 

The charity is under the control of its legal members. 

If the CIO is wound up, the members of the CIO have no liability to contribute to its assets and no personal responsibility for settling its debts and liabilities. 

14 



## **British Psoriatic Arthritis Consortium** 

## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** 

_**This analysis is classsified by conventional nominal descriptions and not by activity.**_ 

## **15 Donations, Grants and Legacies** 

|**Donations and gifts from individuals**<br>**Total Donations, Grants and**<br>**Legacies**<br>**A1**<br>**16 Investment income**<br>Bank Interest Receivable<br>**Total investment income**<br>**A4**<br>Small donations individually less than £1000<br>Novartis<br>**Total sponsorship income**<br>UCB<br>Lilly<br>Sterling University<br>**Total donations and gifts from**<br>**individuals**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>142|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-|**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**142**<br>**142**<br>**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**7,500**<br>**10,000**<br>**7,500**<br>**-**<br>**25,000**|**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>853|
|---|---|---|---|---|
||**142**|**-**||**853**|
||**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>7,500<br>10,000<br>7,500<br>-|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-<br>-<br>-<br>-||**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>10,000<br>10,000<br>15,000<br>7,500|
||**25,000**|**-**||**42,500**|
||||||
||||||
||**25,142**|**-**|**25,142**<br>**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**246**<br>**246**|**43,353**|
||**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>246|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-||**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>212|
||**246**|**-**||**212**|



15 



## **British Psoriatic Arthritis Consortium** 

## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** 

## **17 Expenditure on charitable activities - Direct spending** 

|**_Current Year_**<br>**Total direct spending**<br>**B2a**<br>Sequence project expenses<br>Administration fees<br>Abstract award<br>Course expenses<br>White Swan project expenses<br>Patient Partner expenses|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>4,561<br>500<br>510<br>9,064<br>-<br>12,120|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-<br>-<br>-<br>-<br>7,050<br>-|**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**4,561**<br>**500**<br>**510**<br>**9,064**<br>**7,050**<br>**12,120**<br>**33,805**|**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>**4,469**<br>**600**<br>**1,400**<br>**10,374**<br>**58,050**<br>**-**|
|---|---|---|---|---|
||**26,755**|**7,050**||**74,893**|



## **18 Expenditure on charitable activities- Grant funding of activities** 

|**_Current Year_**<br>**Total grantmaking costs**<br>**B2c**<br>**19**<br>**_Current Year_**<br>**_Premises Expenses_**<br>**_Administrative overheads_**<br>Stationery and printing<br>Rent payable under operating leases<br>**Support costs for charitable activities**<br>Grants awarded<br>Subscriptions<br>Telephone and internet<br>IT support and costs|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>25,000|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-|**Current year**<br>**Prior Year**<br>**Total Funds**<br>**Total Funds**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>**25,000**<br>**50,000**|
|---|---|---|---|
||**25,000**|**-**|**25,000**<br>**50,000**|
||**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>1,850<br>200<br>299<br>220<br>728|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-<br>-<br>-<br>-<br>-|**Current year**<br>**Prior Year**<br>**Total Funds**<br>**Total Funds**<br>**2025**<br>**2024**<br>**£**<br>**£**<br>**1,850**<br>**1,850**<br>**200**<br>**224**<br>**299**<br>**243**<br>**220**<br>**158**<br>**728**<br>**932**|



16 



## **British Psoriatic Arthritis Consortium** 

## **Detailed analysis of income and expenditure for the year ended 31 March 2025 as required by the SORP 2015** 

|**_Financial costs_**<br>**Total support costs**<br>Bank charges<br>Insurance<br>Travel and subsistence<br>Bookkeeping fees<br>Sundry expenses|368<br>-<br>930<br>947<br>70|-<br>-<br>-<br>-<br>-|**368**<br>**-**<br>**930**<br>**947**<br>**70**<br>**5,612**|**368**<br>**47**<br>**756**<br>**-**<br>**72**|
|---|---|---|---|---|
||**5,612**|**-**||**4,650**|
|||||~~**-**~~**-**|



All the expenditure in the prior year was unrestricted. **20 Other Expenditure - Governance costs** 

|**_Current Year_**<br>Independent Examiner's fees<br>**Total Governance costs**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>1,398|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>-|**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**1,398**<br>**1,398**|**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>**1,361**|
|---|---|---|---|---|
||**1,398**|**-**||**1,361**|



All the expenditure in the prior year was unrestricted. 

**21 Total Charitable expenditure** 

|**Total Charitable expenditure**|||||
|---|---|---|---|---|
|**_Current Year_**<br>Total direct spending<br>**B2a**<br>Total grantmaking costs<br>**B2c**<br>Total support costs<br>**B2d**<br>Total Governance costs<br>**B2e**<br>**Total charitable expenditure**<br>**B2**|**Current year**<br>**Unrestricted**<br>**Funds**<br>**2025**<br>**£**<br>26,755<br>25,000<br>5,612<br>1,398|**Current year**<br>**Restricted**<br>**Funds**<br>**2025**<br>**£**<br>7,050<br>-<br>-<br>-|**Current year**<br>**Total Funds**<br>**2025**<br>**£**<br>**33,805**<br>**25,000**<br>**5,612**<br>**1,398**<br>**65,815**|**Prior Year**<br>**Total Funds**<br>**2024**<br>**£**<br>**74,893**<br>**50,000**<br>**4,650**<br>**1,361**|
||**58,765**|**7,050**||**130,904**|



All the expenditure in the prior year was unrestricted. 

|**_Prior Year_**<br>Total direct spending<br>**B2a**<br>Total grantmaking costs<br>**B2c**<br>Total support costs<br>**B2d**<br>Total Governance costs<br>**B2e**<br>**Total charitable expenditure**<br>**B2**|**Prior Year**<br>**Unrestricted**<br>**Funds**<br>**2024**<br>**£**<br>74,893<br>50,000<br>4,650<br>1,361|**Prior Year**<br>**Prior Year**<br>**Restricted**<br>**Funds**<br>**Total Funds**<br>**2024**<br>**2024**<br>**£**<br>**£**<br>-<br>**74,893**<br>-<br>**50,000**<br>-<br>**4,650**<br>-<br>**1,361**|
|---|---|---|
||**130,904**|**-**<br>**130,904**|



17